

**AMENDMENTS TO THE CLAIMS**

1. **(Currently Amended)** A transdermal preparation containing 4-(2-methyl-1-imidazolyl)-2,2-diphenylbutylamide or a medically acceptable salt thereof as the sole active ingredient, and an external preparation base.

2-4. **(Cancelled)**

5. **(Currently Amended)** The preparation according to claim 4claim 1, for use as a prophylactic or therapeutic agent for preventing or treating a disorder in patients with overactive bladder, wherein the disorder is increased urinary frequency and urinary incontinence in patients with overactive bladder.

6. **(Currently Amended)** The preparation according to claim 1, provided in the form of patcha patch.

7. **(Original)** The preparation according to claim 6, provided in the form of a single adhesive layer-type or a reservoir-type transdermal preparation.

8-10. **(Cancelled)**

11. **(Currently Amended)** The A transdermal preparation for treating increased urinary frequency and urinary incontinence according to claim 1, containing as the sole active ingredient 4-(2-methyl-1-imidazolyl)-2,2-diphenylbutylamide or a medically acceptable salt thereof, and comprising an external preparation base and a structural body.

12. **(Cancelled)**

13. (Currently Amended) The transdermal preparation for treating increased urinary frequency and urinary incontinence according to claim 11, which is of a reservoir type preparation, comprising:

~~wherein a mixture of 4-(2-methyl-1-imidazolyl)-2,2-diphenylbutylamide as the sole active ingredient is present in a mixture with and a single or combination one or more of the external preparation bases; and~~

~~wherein the a-structural body comprising comprises a membrane for controlling drug permeation, an adhesive layer, a support, and a peelable liner.~~

14-16. (Cancelled)

17. (New) The transdermal preparation for treating increased urinary frequency and urinary incontinence according to claim 11, which is of a single adhesive layer type preparation,

wherein 4-(2-methyl-1-imidazolyl)-2,2-diphenylbutylamide or a medically acceptable salt thereof is present in an adhesive layer containing styrene-isobutylene-styrene block copolymer and ultra-pale rosin ester as the external preparation bases; and

wherein the structural body comprises a support and a peelable liner.

18. (New) The transdermal preparation for treating increased urinary frequency and urinary incontinence according to claim 13, wherein the external preparation bases comprise hydroxypropylmethylcellulose (HPMC), and ethanol/water mixture.

19. (New) The preparation according to claim 1, wherein the transdermal preparation is provided in the form of a single adhesive layer-type transdermal preparation, and the external preparation bases comprise styrene-isobutylene-styrene block copolymer and ultra-pale rosin ester.

20. (New) The preparation according to claim 1, wherein the transdermal preparation is provided in the form of a reservoir-type transdermal preparation, and the external preparation bases comprise hydroxypropylmethylcellulose (HPMC), and ethanol/water mixture.

21. (New) A method for preventing or treating increased urinary frequency or urinary incontinence in patients with overactive bladder, comprising administering a therapeutically effective amount of the preparation according to claim 1 to the patient with the overactive bladder.

22. (New) A method for preventing or treating increased urinary frequency or urinary incontinence in patients with overactive bladder, comprising administering a therapeutically effective amount of the preparation according to claim 11 to the patient with the overactive bladder.